Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

La Jolla Riquent NDA Planned For Year-End; Will Seek Accelerated Approval

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

La Jolla Pharmaceuticals will pursue accelerated approval for its systemic lupus erythematosus agent Riquent (formerly LJP 394).
Advertisement

Related Content

Riquent "Approvable" For Lupus; FDA Says Ongoing Study Could Be Enough
FDA Lupus Trial Design Guidance Will Go To Advisory Committee In Fall
FDA Lupus Trial Design Guidance Will Go To Advisory Committee In Fall
FDA Lupus Trial Design Guidance Will Go To Advisory Committee In Fall

Topics

Advertisement
UsernamePublicRestriction

Register

PS002272

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel